Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Tax Provisions (2024 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Tax Provisions for 4 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 88.53% year-over-year to -$1.0 million, compared with a TTM value of $43.2 million through Dec 2025, down 2.3%, and an annual FY2025 reading of -$1.0 million, down 102.3% over the prior year.
  • Tax Provisions was -$1.0 million for Q4 2025 at Agios Pharmaceuticals, up from -$8.9 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $53.1 million in Q3 2024 and bottomed at -$8.9 million in Q4 2024.